Composition for treating sepsis or septic shock comprising the peptide originated from the Smad6
US9227997B2 · kind B2 · utility
3Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 28, 2012 |
| Grant date | Jan 5, 2016 |
| Priority date | — |
| Expiry date | Dec 28, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K1/1077
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a pharmaceutical composition comprising a Smad6-derived peptide as an active ingredient. Having ability to specifically bind to Pellino-1, the Smad6-derived peptide is effectively useful in the treatment of the sepsis mediated by excessively activated TLR. The peptide effectively reduces the expression of inflammatory cytokines, protects cells from sepsis-induced apoptosis, and exhibits high bacterial clearance in animal models of sepsis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.